Corrigendum to "Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase" [Bioorg. Med. Chem. Lett. 29 (2019) 1918-1921].

作者信息

Kim Soong-Hoon, Johnson James A, Jiang Ji, Parkhurst Brandon, Phillips Monique, Pi Zulan, Qiao Jennifer X, Tora George, Ye Chen Alice, Liu Eddie, Yin Xiaohong, Yang Richard, Zhao Lei, Taylor David S, Basso Michael, Behnia Kamelia, Onorato Joelle, Chen Xue-Qing, Abell Lynn M, Lu Hao, Locke Gregory, Caporuscio Christian, Adam Leonard P, Gordon David, Wexler Ruth R, Finlay Heather J

机构信息

Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States.

出版信息

Bioorg Med Chem Lett. 2019 Sep 1;29(17):2525. doi: 10.1016/j.bmcl.2019.07.032. Epub 2019 Jul 25.

DOI:10.1016/j.bmcl.2019.07.032

PMID:31353296

Abstract

摘要

相似文献

Corrigendum to "Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase" [Bioorg. Med. Chem. Lett. 29 (2019) 1918-1921].

Bioorg Med Chem Lett. 2019 Sep 1;29(17):2525. doi: 10.1016/j.bmcl.2019.07.032. Epub 2019 Jul 25.

Corrigendum to "Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors" [Bioorg. Med. Chem. Lett. 31 (2021) 127710].对“鉴定2-取代吡咯并[1,2-b]哒嗪衍生物作为新型PARP-1抑制剂”[《生物有机与药物化学快报》31 (2021) 127710]的勘误

Bioorg Med Chem Lett. 2022 Jan 15;56:128501. doi: 10.1016/j.bmcl.2021.128501. Epub 2021 Dec 12.

Corrigendum to "Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors" [Bioorg. Med. Chem. Lett. 60 (2022) 128549].

Bioorg Med Chem Lett. 2022 Sep 15;72:128856. doi: 10.1016/j.bmcl.2022.128856. Epub 2022 Jun 18.

Corrigendum to "Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors" [Bioorg. Med. Chem. Lett. 24 (2014) 5093-5097].

Bioorg Med Chem Lett. 2017 Jul 15;27(14):3205. doi: 10.1016/j.bmcl.2017.05.056. Epub 2017 May 24.

Corrigendum to "Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury" [Bioorg. Med. Chem. Lett. 29(8) (2019) 995-1000].《“发现并优化一种用于潜在治疗神经损伤的强效、选择性且口服生物可利用的RARβ激动剂”的勘误》[《生物有机与药物化学快报》29(8) (2019) 995 - 1000]

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2440-2441. doi: 10.1016/j.bmcl.2019.05.058. Epub 2019 Jun 14.

Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675].

Bioorg Med Chem Lett. 2020 Jan 15;30(2):126771. doi: 10.1016/j.bmcl.2019.126771. Epub 2019 Dec 16.

Corrigendum to "Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow" [Bioorg. Med. Chem. Lett. 29 (2019) 2575-2580].

Bioorg Med Chem Lett. 2020 Aug 15;30(16):127363. doi: 10.1016/j.bmcl.2020.127363. Epub 2020 Jun 23.

Corrigendum to "Synthesis and carbonic anhydrase inhibitory properties of novel chalcone substituted benzenesulfonamides" [Bioorg. Med. Chem. Lett. 26 (2016) 5867-5870].《新型查尔酮取代苯磺酰胺的合成及其碳酸酐酶抑制活性》的勘误 [《生物有机与药物化学快报》26 (2016) 5867 - 5870]

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3944. doi: 10.1016/j.bmcl.2017.02.074. Epub 2017 Jul 10.

Corrigendum to "Structure guided development of potent piperazine-derived hydroxamic acid inhibitors targeting falcilysin" [Bioorg. Med. Chem. Lett. 32 (2021) 127683].《针对falcilysin的强效哌嗪衍生异羟肟酸抑制剂的结构导向开发》的勘误[《生物有机与药物化学快报》32 (2021) 127683]

Bioorg Med Chem Lett. 2021 Apr 1;37:127836. doi: 10.1016/j.bmcl.2021.127836. Epub 2021 Feb 13.

Corrigendum to "Biochemical, cellular and structural characterization of novel and selective ERK3 inhibitors" [Bioorg. Med. Chem. Lett. 30 (2020) 127551].

Bioorg Med Chem Lett. 2021 Oct 1;49:128262. doi: 10.1016/j.bmcl.2021.128262. Epub 2021 Aug 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验